Phase IIb Study of STA-2 in Patients With Chronic Stable Angina

Status Completed

Clinical Trial Summary

Clinical Trial Description

The objective of this study is to evaluate the dose-response of three different dose levels of STA-2 (900 mg daily, 1800 mg daily and 2700 mg daily for 42 days) versus placebo in patients with chronic stable angina.

Treatment Group A:

150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)

Treatment Group B:

300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)

Treatment Group C:

450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)

Placebo Group:

Placebo capsule, 2 capsules t.i.d., after meal ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01239511
Study type	Interventional
Source	Sinphar Pharmaceutical Co., Ltd
Contact
Status	Completed
Phase	Phase 2
Start date	November 2010
Completion date	April 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02908776` - MYocardial DAmage AND MIcrobiota STUDY	N/A
Recruiting	`NCT01397994` - Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.	Phase 4
Active, not recruiting	`NCT00350922` - A Clinical Trial of a Self-Management Education Program for People With Chronic Stable Angina	Phase 1
Completed	`NCT02078921` - The Effects of Inorganic Nitrate on Cardiac Muscle in Angina	Phase 2
Completed	`NCT02591758` - Novel Vitality Indices Derived From the Hexoskin in Patients Affected With Angina Undergoing Coronary Revascularization or Medical Therapy
Terminated	`NCT03346278` - Text Message Intervention to Improve Cardiac Rehab Participation	N/A
Active, not recruiting	`NCT06249581` - Pharmacokinetics of AUX-001 40mg Once-daily in Healthy Subjects Under Fasting and Fed Conditions	Early Phase 1
Enrolling by invitation	`NCT03063697` - Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure	N/A
Completed	`NCT02722213` - Mindfulness & Stress Management Study for Cardiac Patients	N/A
Completed	`NCT01484912` - Phase II Study of STA-2 in Patients With Chronic Stable Angina	Phase 2
Recruiting	`NCT03507361` - Myocardial Damage and Music Study	N/A
Recruiting	`NCT03834155` - Enhancing Cardiac Rehabilitation Through Behavioral Nudges	N/A
Active, not recruiting	`NCT02710435` - REDUCER-I: An Observational Study of the Neovasc Reducer™ System
Withdrawn	`NCT00518921` - Capadenoson in Angina Pectoris	Phase 2
Withdrawn	`NCT02423265` - Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries	Phase 4
Completed	`NCT01369472` - Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule	Phase 1
Completed	`NCT01340248` - A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers	Phase 1
Completed	`NCT02315001` - Liraglutide to Improve corONary Haemodynamics During Exercise streSS	Phase 2
Completed	`NCT01760083` - A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions	N/A
Unknown status	`NCT01558830` - Safety of Amiodarone and Ranolazine Together in Patients With Angina	Phase 4